Transformed by His Promises Offers a 12-Week Journey to Emotional and Behavioral Freedom
Released in time for World Mental Health Day, "Transformed by His Promises" equips readers with clinically informed strategies and structured...
Brain
Spring Health Convenes AI in Mental Health Safety & Ethics Council to Set Industry Standards for Responsible AI
NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Today, a coalition of leaders from academia, healthcare, technology, and employee benefits announced the...
Cognixion Launches Clinical Study Integrating Non-Invasive Brain-Computer Interface Technology
Study to accelerate access to brain-computer interface technology, using Apple Vision Pro, for people with ALS, spinal cord injury (SCI),...
Cognixion Launches Clinical Study Integrating Non-Invasive Brain-Computer Interface Technology
Study to accelerate access to brain-computer interface technology, using Apple Vision Pro, for people with ALS, spinal cord injury (SCI),...
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin volume, resulting...
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company...
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead...
Solid Biosciences to Present at Upcoming Scientific Meetings
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic...
Creyos Recognized as Quarterfinalist for the 2025 Digital Health Hub Foundation: Digital Health Awards
TORONTO, Sept. 30, 2025 /PRNewswire/ -- Creyos, the digital platform reshaping brain health assessment in clinical care, is thrilled to announce...
The ADDF’s Diagnostics Accelerator Unveils SpeechDx Dataset and New Partnership to Catalyze Breakthroughs in Speech-Based Biomarkers
The gold-standard dataset will power a new generation of AI tools to forecast Alzheimer's risk, track progression, and guide interventions...
Neurophet Publishes Clinical Validation Results of ‘Neurophet AQUA’ in Annals Academy of Medicine Singapore
- Clinical study conducted at the Dementia Research Centre, Nanyang Technological University, Singapore, involving Southeast Asian participants - Expert level accuracy,...
AIML and BC Brain Wellness Program Launch Pilot to Explore the Heart–Brain Connection
Leveraging MaxYield™ ECG to capture real-world exercise data in people living with neurological conditionsGenerating actionable insights into how cardiac responses...
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial
Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of...
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and...
gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia
Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2...
BrainCo Empowers Quan to Share His “Life Without Limits”
BOSTON, Sept. 30, 2025 /PRNewswire/ -- BrainCo holds that the true value of technology lies in expanding the boundaries of...
Natus Acquires Holberg EEG, Expanding Innovation in Neurodiagnostic AI Solutions
MIDDLETON, Wis., Sept. 30, 2025 /PRNewswire/ -- Natus Medical Incorporated, the largest global pure-play neurodiagnostics company, today announced it has...
Pier 88 Health and Theranica Announce China NMPA Approval of the Nerivio® REN wearable for Acute Treatment of Migraine
First and Only REN-Based Migraine Treatment Approved in China BEIJING and NETANYA, Israel, Sept. 29, 2025 /PRNewswire/ -- Pier 88 Health, a...
Angle PLC Announces Presentation of Data on Glioblastoma
CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma PatientsGBM CTC isolation only possible with Parsortix label-free methodologyData presented at the...